Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes
Prescriber's specialty strongly determined the selection of cardioprotective agents. Treatment guidelines should provide more specific guidance regarding patient selection and consider the holistic benefits of each drug class beyond their cardiovascular protective effects.
Authors
- Ildiko Lingvay (ORCID: https://orcid.org/0000-0001-7006-7401)
- Jonathan Pak
- Daniel F. Heitjan (ORCID: https://orcid.org/0000-0002-1527-4472)
- Michael E. Bowen (ORCID: https://orcid.org/0000-0003-4089-1584)
- KELSEA MARBLE
- Christine Mai
- Zichang Xiang
- Shubham Agarwal (ORCID: https://orcid.org/0000-0002-0975-4752)
- Mujeeb Basit
Institutions
- Southern Methodist University (US)
- Southwestern Medical Center (US)
- Boehringer Ingelheim (United States) (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-05-23
- DOI
- https://doi.org/10.3389/fcvm.2025.1606198
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Boehringer Ingelheim
- Eli Lilly and Company